Incyte | INCY - Ebitda


Incyte reported $778.57M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
Agenus USD -10.11M 19.02M Mar/2025
Agios Pharmaceuticals USD -108.66M 11.65M Mar/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Amgen USD 3.86B 1.28B Mar/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Eli Lilly USD 10.29B 1.86B Mar/2026
Exelixis USD 258.29M 15.43M Mar/2026
Gilead Sciences USD 3.51B 489M Mar/2026
Incyte USD 778.57M 410.6M Jun/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
MacroGenics USD -30.2M 52.15M Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Moderna USD -1.26B 468M Mar/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Novartis USD 5.41B 431M Mar/2026
Pfizer USD 6.01B 18M Jun/2026
PTC Therapeutics USD 61.98M 132.97M Mar/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026